Studies blood changes in people with ovarian and other solid cancers
Observes clonal blood changes and later blood cancers in people with solid cancers.
Plain-language title generated from the registry record
Registry title: Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Key facts
- Where
- Seattle, United StatesSee the site
Where in United States
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Washington
- Trial code
- NCT06295965
- Record updated
- 6 November 2026
- Original description
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.Read full original descriptionShow less
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
Inclusion: Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:; Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy; OR; Subjects who have or have had a solid tumor diagnosis and any of the following:; At least 4 months of exposure to a PARP inhibitor; Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm.
Exclusion: Individuals with a life expectancy of less than 6 months.